Rasuvo is owned by Medexus.
Rasuvo contains Methotrexate.
Rasuvo has a total of 1 drug patent out of which 0 drug patents have expired.
Rasuvo was authorised for market use on 10 July, 2014.
Rasuvo is available in solution;subcutaneous dosage forms.
Rasuvo can be used as subcutaneous injection of methotrexate.
The generics of Rasuvo are possible to be released after 01 June, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8664231||MEDEXUS||Concentrated methotrexate solutions|| |
(6 years from now)
Market Authorisation Date: 10 July, 2014
Treatment: Subcutaneous injection of methotrexate
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic